MultiCell Technologies, Inc. (MCET) news stock charts
MultiCell Technologies, Inc. (MCET/MCET.OB) Investment Summary:
MultiCell Technologies, Inc., a biopharmaceutical company, develops and commercializes therapeutics based on a portfolio of patented drug development technology platforms. The company involves in the research and development of degenerative neurological diseases, including multiple sclerosis (MS) and cancer. Its therapeutic pipeline includes MCT-125, a Phase IIb therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-175, a preclinical therapeutic candidate for the treatment of relapsing-remitting MS; MCT-465, a preclinical adjuvant therapeutic candidate for the treatment of TLR3+ cancers; and MCT-475, a preclinical therapeutic candidate for the treatment o...MULTICELL TECHNOLOGIES INC (MCET:OTC Bulletin Board Market)
Snapshot of MULTICELL TECHNOLOGIES INC (MCET)
|
OPEN
$0.01
|
PREVIOUS CLOSE
$0.01
|
|
|
DAY HIGH
$0.01
|
DAY LOW
$0.01
|
|
|
52 WEEK HIGH
08/20/09 - $0.04
|
52 WEEK LOW
07/21/09 - $0.0065
|
|
|
MARKET CAP
3.6M
|
AVERAGE VOLUME 10 D
1.8M
|
|
|
EPS TTM
--
|
SHARES OUTSTANDING
327.4M
|
|
|
MCET Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for MULTICELL TECHNOLOGIES INC (MCET)
MultiCell Technologies, Inc. recently provided analysis of its financial condition. The company said, We will have to raise additional capital in order to initiate Phase IIb clinical trials for MCT-125, the Company's therapeutic product for the treatment of fatigue in multiple sclerosis patients. Management is evaluating several sources of financing for its clinical trial program. Additionally, with our strategic shift in focus to therapeutic programs and technologies, we expect our future cash requirements to increase significantly as we advance our therapeutic programs into clinical trials. Until we are successful in raising additional funds, we may have to prioritize our therapeutic programs and delays may be necessary in some of our development programs.
On 04/13/2009, MultiCell Technologies, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
MultiCell Technologies Inc. announced that it has entered into a cooperative research and development agreement with Maxim Biotech Inc. to develop products for the study of liver stem cells and liver cancer. Tumor tissues are composed of a mixture of cells with some tumor cells exhibiting stem cell-like properties. Cancer stem cells are thought to play a role in a tumor's resistance to therapy. While significant progress has been made in developing cancer therapies that result in cytoreduction and thus tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. Cancer stem cells are believed to be responsible for cancer relapse by being less sensitive to conventional therapies. Cancer stem cells may offer a unique opportunity to identify and develop a new generation of more effective anticancer agents. The cooperative research and development agreement with Maxim Biotech Inc. will initially focus on the development of a family of life science research reagent tool kits which can be used to isolate liver stem cells, and help to elucidate liver stem cell gene function and their encoded proteins. MultiCell plans to further leverage this research effort involving liver stem cells to identify therapeutic targets, and diagnostic and prognostic markers of liver cancer. MultiCell will also seek to develop and patent therapeutic product opportunities specifically targeting the treatment of primary liver cancer and intrahepatic bile duct cancer.
MultiCell Technologies, Inc. financial resources
MCET Competitors
| Company | Last | Change | |
| No competitor information is available for MCET. | |||
| Market data is delayed at least 15 minutes. | |||
Industry Analysis
| Valuation | MCET | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 11.4x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 3.7x |
|
|
MCET |
||
MCET transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent Financial News About MultiCell Technologies, Inc.
MULTICELL TECHNOLOGIES, INC. Files SEC form 10-K, Annual Report
Read article
Skymark Research Initiates Independent Research Coverage On MultiCell Technologies, Inc.
Read article
Skymark Research Initiates Independent Research Coverage On MultiCell Technologies, Inc.
Read article
MULTICELL TECHNOLOGIES, INC. Files SEC form 10-K, Annual Report
Read article
MULTICELL TECHNOLOGIES, INC. Files SEC form 10-Q, Quarterly Report
Read article
MULTICELL TECHNOLOGIES, INC. Files SEC form 10-Q, Quarterly Report
Read article
MULTICELL TECHNOLOGIES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events
Read article
MULTICELL TECHNOLOGIES, INC. Files SEC form 10-Q, Quarterly Report
Read article